Journal: EBioMedicine
Article Title: Reversing pathology in a preclinical model of Alzheimer's disease by hacking cerebrovascular neoangiogenesis with advanced cancer therapeutics.
doi: 10.1016/j.ebiom.2021.103503
Figure Lengend Snippet: Fig. 5. Examination of tight junction proteins by immunofluorescence microscopy in the brains of Tg2576 mice and their WT littermates. a) Brains from perfused mice were used for immunofluorescence analysis of the BBB. Cortical brain sections were stained for the combination of markers CD105, CD31 and the tight junction protein, Occludin. Panel a) shows a micrograph of the cortical region of the brain with merged CD31 (red), CD105 (green) and Occludin (blue) staining whereas the other three panels show CD31, CD105 and Occludin where the field of view was enlarged to reveal a more detailed view of the structures. b) The percentage of tight junction protein disruption is shown graphically (WT B6SJL n= 5 and Tg2576 n= 6). The data are representative of three separate experiments (two-tailed unpaired t-test, * p<0.03; ** p<0.002; *** p<0.0002; **** p<0.0001). c) Images of the brain show an intact BBB and a disrupted BBB. Evans Blue staining is normally very low when the BBB is intact. Post-treatment with Evans Blue, the harvested brains from WT mice showed no colouration, while the brains from vehicle-treated Tg2576 mice appeared blue. d) Post-treatment with Evans Blue, the dye was extracted from the brains, minus the olfactory bulbs and the cerebellum. The absorbance of the extracted dye was read with an ELISA plate reader at 620 nm, and the readings were divided by the weight of the brain. An increase in the uptake of Evans Blue in the brain homogenates prepared from the vehicle-treated Tg2576 mice was indicated by the high absorbance of the dye. No difference was observed between the vehicle- and drug-treated WT (B6/SJL) mice. Axitinib treatment of the Tg2576 mice resulted in less Evans Blue staining than in the vehicle-treated ani- mals, thereby indicating restoration of a functioning BBB. This experiment was repeated twice. (two-tailed unpaired t-test, * p<0.03; ** p<0.002; *** p<0.0002; **** p<0.0001). e) The cortical micrographs here show the voxels of the field of view of the imaged sections represented by the grid. The micrographs are representative of brain sections from mice from a separate experiment, where both Tg2576 and WT animals were treated with Axitinib or delivery vehicle alone, followed by staining for albumin. Red indicates immuno- stained albumin that has leaked into the brain and cyan indicates the cell nucleus (stained with DAPI). Axitinib treatment was associated with less albumin leakage into the brain, indicative of a more functional BBB, in contrast to the greater albumin staining in the vehicle-treated Tg2576. f) The quantification of Albumin is shown as the percentage of pixels in each field of view (n=3). The data are represented as the mean§ standard deviation. Statistical analysis was performed using an unpaired two-tailed t-test. (* p<0.03; ** p<0.002; *** p<0.0002; **** p<0.0001).(For interpretation of the references to colour in this figure, the reader is referred to the web version of this article.)
Article Snippet: Antibodies used for immunoblots, immunofluorescence and immunoprecipitation (concentrations were used according to company datasheets unless indicated otherwise): Goat anti-human endoglin / CD105 polyclonal antibody (RRID: AB_354598 R&D systems; AF1097 https://resources.rndsystems.com/pdfs/datasheets/af1097. pdf?v=20210622&_ga=2.123831427.868075561.16243931411326343303.1619741954), anti-b-Amyloid, 1-16 clone 6E-10 (BioLegend; 39320 https://www.biolegend.com/en-us/global-elements/ pdf-popup/purified-anti-beta-amyloid-1-16-antibody-11228?filename=Purified%20anti-beta-Amyloid%201-16%20%20Antibody. pdf&pdfgen=true), Polyclonal Antibody Z0-1 (RRID: AB_2533938 ThermoFisher Scientific; cat. # 61-7300 https://www.thermofisher. com/order/genome-database/dataSheetPdf?producttype=antibody& productsubtype=antibody_primary&productId=61-7300&ver sion=156), Recombinant anti-GAPDH antibody [EPR16891] (RRID: AB_2630358 abcam; ab181602), anti-Actin (C-11) antibody (RRID: AB_630835 Santa Cruz Biotechnology; sc1615 https://search.cosmo bio.co.jp/cosmo_search_p/search_gate2/docs/SCB_/ SC1615.20070227.pdf), rabbit anti-human occludin polyclonal antibody (RRID: AB_881773 abcam; ab31721), anti-CD31 antibody (RRID: AB_726362 abcam; ab28364), anti-mouse serum albumin antibody (RRID: AB_777886 abcam; ab19194), anti-amyloid (1-16) antibody 6E10 (Biolegend; cat. # 803002 https://www.biolegend. com/en-us/global-elements/pdf-popup/purified-anti-beta-amyloid1-16-antibody-11228?filename=Purified%20anti-beta-Amyloid%20116%20%20Antibody.pdf&pdfgen=true), beta Amyloid 1-42 anti-amyloid antibody (RRID: AB_867645 abcam; ab39377).
Techniques: Microscopy, Staining, Disruption, Two Tailed Test, Enzyme-linked Immunosorbent Assay, Functional Assay, Standard Deviation